AIH Therapy: Beyond First-Line

Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Adao, Irina [verfasserIn] Klepper, Arielle [verfasserIn] Tana, Michele [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	Autoimmune hepatitis Second-line therapy Third-line therapy AIH treatment

Anmerkung:	© The Author(s) 2024

Übergeordnetes Werk:	Enthalten in: Current transplantation reports - Springer US, 2002, 23(2024), 3 vom: 08. März, Seite 341-348
Übergeordnetes Werk:	volume:23 ; year:2024 ; number:3 ; day:08 ; month:03 ; pages:341-348

Links:	Volltext

DOI / URN:	10.1007/s11901-024-00657-4

Katalog-ID:	SPR056869592

Internformat


LEADER	01000naa a22002652 4500
001	SPR056869592
003	DE-627
005	20240807064713.0
007	cr uuu---uuuuu
008	240807s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11901-024-00657-4 \|2 doi
035			\|a (DE-627)SPR056869592
035			\|a (SPR)s11901-024-00657-4-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
100	1		\|a Adao, Irina \|e verfasserin \|4 aut
245	1	0	\|a AIH Therapy: Beyond First-Line
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2024
520			\|a Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies.
650		4	\|a Autoimmune hepatitis \|7 (dpeaa)DE-He213
650		4	\|a Second-line therapy \|7 (dpeaa)DE-He213
650		4	\|a Third-line therapy \|7 (dpeaa)DE-He213
650		4	\|a AIH treatment \|7 (dpeaa)DE-He213
700	1		\|a Klepper, Arielle \|e verfasserin \|4 aut
700	1		\|a Tana, Michele \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Current transplantation reports \|d Springer US, 2002 \|g 23(2024), 3 vom: 08. März, Seite 341-348 \|h Online-Ressource \|w (DE-627)787023302 \|w (DE-600)2772824-9 \|w (DE-576)407570381 \|x 2195-9595 \|7 nnns
773	1	8	\|g volume:23 \|g year:2024 \|g number:3 \|g day:08 \|g month:03 \|g pages:341-348
856	4	0	\|u https://dx.doi.org/10.1007/s11901-024-00657-4 \|m X:SPRINGER \|x Resolving-System \|z kostenfrei \|3 Volltext
912			\|a SYSFLAG_0
912			\|a GBV_SPRINGER
951			\|a AR
952			\|d 23 \|j 2024 \|e 3 \|b 08 \|c 03 \|h 341-348

Indexfelder

author_variant	i a ia a k ak m t mt
matchkey_str	article:21959595:2024----::iteayeodi
hierarchy_sort_str	2024
publishDate	2024
allfields	10.1007/s11901-024-00657-4 doi (DE-627)SPR056869592 (SPR)s11901-024-00657-4-e DE-627 ger DE-627 rakwb eng 610 VZ Adao, Irina verfasserin aut AIH Therapy: Beyond First-Line 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213 Klepper, Arielle verfasserin aut Tana, Michele verfasserin aut Enthalten in Current transplantation reports Springer US, 2002 23(2024), 3 vom: 08. März, Seite 341-348 Online-Ressource (DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381 2195-9595 nnns volume:23 year:2024 number:3 day:08 month:03 pages:341-348 https://dx.doi.org/10.1007/s11901-024-00657-4 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER AR 23 2024 3 08 03 341-348
spelling	10.1007/s11901-024-00657-4 doi (DE-627)SPR056869592 (SPR)s11901-024-00657-4-e DE-627 ger DE-627 rakwb eng 610 VZ Adao, Irina verfasserin aut AIH Therapy: Beyond First-Line 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213 Klepper, Arielle verfasserin aut Tana, Michele verfasserin aut Enthalten in Current transplantation reports Springer US, 2002 23(2024), 3 vom: 08. März, Seite 341-348 Online-Ressource (DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381 2195-9595 nnns volume:23 year:2024 number:3 day:08 month:03 pages:341-348 https://dx.doi.org/10.1007/s11901-024-00657-4 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER AR 23 2024 3 08 03 341-348
allfields_unstemmed	10.1007/s11901-024-00657-4 doi (DE-627)SPR056869592 (SPR)s11901-024-00657-4-e DE-627 ger DE-627 rakwb eng 610 VZ Adao, Irina verfasserin aut AIH Therapy: Beyond First-Line 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213 Klepper, Arielle verfasserin aut Tana, Michele verfasserin aut Enthalten in Current transplantation reports Springer US, 2002 23(2024), 3 vom: 08. März, Seite 341-348 Online-Ressource (DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381 2195-9595 nnns volume:23 year:2024 number:3 day:08 month:03 pages:341-348 https://dx.doi.org/10.1007/s11901-024-00657-4 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER AR 23 2024 3 08 03 341-348
allfieldsGer	10.1007/s11901-024-00657-4 doi (DE-627)SPR056869592 (SPR)s11901-024-00657-4-e DE-627 ger DE-627 rakwb eng 610 VZ Adao, Irina verfasserin aut AIH Therapy: Beyond First-Line 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213 Klepper, Arielle verfasserin aut Tana, Michele verfasserin aut Enthalten in Current transplantation reports Springer US, 2002 23(2024), 3 vom: 08. März, Seite 341-348 Online-Ressource (DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381 2195-9595 nnns volume:23 year:2024 number:3 day:08 month:03 pages:341-348 https://dx.doi.org/10.1007/s11901-024-00657-4 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER AR 23 2024 3 08 03 341-348
allfieldsSound	10.1007/s11901-024-00657-4 doi (DE-627)SPR056869592 (SPR)s11901-024-00657-4-e DE-627 ger DE-627 rakwb eng 610 VZ Adao, Irina verfasserin aut AIH Therapy: Beyond First-Line 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213 Klepper, Arielle verfasserin aut Tana, Michele verfasserin aut Enthalten in Current transplantation reports Springer US, 2002 23(2024), 3 vom: 08. März, Seite 341-348 Online-Ressource (DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381 2195-9595 nnns volume:23 year:2024 number:3 day:08 month:03 pages:341-348 https://dx.doi.org/10.1007/s11901-024-00657-4 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER AR 23 2024 3 08 03 341-348
language	English
source	Enthalten in Current transplantation reports 23(2024), 3 vom: 08. März, Seite 341-348 volume:23 year:2024 number:3 day:08 month:03 pages:341-348
sourceStr	Enthalten in Current transplantation reports 23(2024), 3 vom: 08. März, Seite 341-348 volume:23 year:2024 number:3 day:08 month:03 pages:341-348
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Autoimmune hepatitis Second-line therapy Third-line therapy AIH treatment
dewey-raw	610
isfreeaccess_bool	true
container_title	Current transplantation reports
authorswithroles_txt_mv	Adao, Irina @@aut@@ Klepper, Arielle @@aut@@ Tana, Michele @@aut@@
publishDateDaySort_date	2024-03-08T00:00:00Z
hierarchy_top_id	787023302
dewey-sort	3610
id	SPR056869592
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056869592</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240807064713.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240807s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11901-024-00657-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056869592</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11901-024-00657-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adao, Irina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">AIH Therapy: Beyond First-Line</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune hepatitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Third-line therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIH treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klepper, Arielle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tana, Michele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current transplantation reports</subfield><subfield code="d">Springer US, 2002</subfield><subfield code="g">23(2024), 3 vom: 08. März, Seite 341-348</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)787023302</subfield><subfield code="w">(DE-600)2772824-9</subfield><subfield code="w">(DE-576)407570381</subfield><subfield code="x">2195-9595</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:3</subfield><subfield code="g">day:08</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:341-348</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11901-024-00657-4</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2024</subfield><subfield code="e">3</subfield><subfield code="b">08</subfield><subfield code="c">03</subfield><subfield code="h">341-348</subfield></datafield></record></collection>
author	Adao, Irina
spellingShingle	Adao, Irina ddc 610 misc Autoimmune hepatitis misc Second-line therapy misc Third-line therapy misc AIH treatment AIH Therapy: Beyond First-Line
authorStr	Adao, Irina
ppnlink_with_tag_str_mv	@@773@@(DE-627)787023302
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2195-9595
topic_title	610 VZ AIH Therapy: Beyond First-Line Autoimmune hepatitis (dpeaa)DE-He213 Second-line therapy (dpeaa)DE-He213 Third-line therapy (dpeaa)DE-He213 AIH treatment (dpeaa)DE-He213
topic	ddc 610 misc Autoimmune hepatitis misc Second-line therapy misc Third-line therapy misc AIH treatment
topic_unstemmed	ddc 610 misc Autoimmune hepatitis misc Second-line therapy misc Third-line therapy misc AIH treatment
topic_browse	ddc 610 misc Autoimmune hepatitis misc Second-line therapy misc Third-line therapy misc AIH treatment
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Current transplantation reports
hierarchy_parent_id	787023302
dewey-tens	610 - Medicine & health
hierarchy_top_title	Current transplantation reports
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)787023302 (DE-600)2772824-9 (DE-576)407570381
title	AIH Therapy: Beyond First-Line
ctrlnum	(DE-627)SPR056869592 (SPR)s11901-024-00657-4-e
title_full	AIH Therapy: Beyond First-Line
author_sort	Adao, Irina
journal	Current transplantation reports
journalStr	Current transplantation reports
lang_code	eng
isOA_bool	true
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
container_start_page	341
author_browse	Adao, Irina Klepper, Arielle Tana, Michele
container_volume	23
class	610 VZ
format_se	Elektronische Aufsätze
author-letter	Adao, Irina
doi_str_mv	10.1007/s11901-024-00657-4
dewey-full	610
author2-role	verfasserin
title_sort	aih therapy: beyond first-line
title_auth	AIH Therapy: Beyond First-Line
abstract	Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. © The Author(s) 2024
abstractGer	Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. © The Author(s) 2024
abstract_unstemmed	Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. © The Author(s) 2024
collection_details	SYSFLAG_0 GBV_SPRINGER
container_issue	3
title_short	AIH Therapy: Beyond First-Line
url	https://dx.doi.org/10.1007/s11901-024-00657-4
remote_bool	true
author2	Klepper, Arielle Tana, Michele
author2Str	Klepper, Arielle Tana, Michele
ppnlink	787023302
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1007/s11901-024-00657-4
up_date	2024-08-07T04:49:22.923Z
_version_	1806702910294196224
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056869592</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240807064713.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240807s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11901-024-00657-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056869592</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11901-024-00657-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adao, Irina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">AIH Therapy: Beyond First-Line</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose of Review The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Autoimmune hepatitis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Third-line therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AIH treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klepper, Arielle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tana, Michele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current transplantation reports</subfield><subfield code="d">Springer US, 2002</subfield><subfield code="g">23(2024), 3 vom: 08. März, Seite 341-348</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)787023302</subfield><subfield code="w">(DE-600)2772824-9</subfield><subfield code="w">(DE-576)407570381</subfield><subfield code="x">2195-9595</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:3</subfield><subfield code="g">day:08</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:341-348</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11901-024-00657-4</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2024</subfield><subfield code="e">3</subfield><subfield code="b">08</subfield><subfield code="c">03</subfield><subfield code="h">341-348</subfield></datafield></record></collection>
score	7.398386

Nicht das Richtige dabei?

Schreiben Sie uns!

AIH Therapy: Beyond First-Line

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?